Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3)

Autor: Liang, X, Chien, HC, Yee, SW, Giacomini, MM, Chen, EC, Piao, M, Hao, J, Twelves, J, Lepist, EI, Ray, AS, Giacomini, KM

Publikováno v: Molecular pharmaceutics, vol 12, iss 12
Liang, X; Chien, HC; Yee, SW; Giacomini, MM; Chen, EC; Piao, M; et al.(2015). Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Molecular Pharmaceutics, 12(12), 4301-4310. doi: 10.1021/acs.molpharmaceut.5b00501. UCSF: Retrieved from: http://www.escholarship.org/uc/item/4mb4p3rn

© 2015 American Chemical Society. The biguanide metformin is widely used as first-line therapy for the treatment of type 2 diabetes. Predominately a cation at physiological pH's, metformin is transported by membrane transporters, which play major ro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::22b0b5c1c7df661c673982c23389a059
https://escholarship.org/uc/item/4mb4p3rn

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Dual inhibition of α v β 6 and α v β 1 reduces fibrogenesis in lung tissue explants from patients with IPF.

Autor: Decaris ML; Pliant Therapeutics, South San Francisco, CA, USA., Schaub JR; Pliant Therapeutics, South San Francisco, CA, USA., Chen C; Pliant Therapeutics, South San Francisco, CA, USA., Cha J; Pliant Therapeutics, South San Francisco, CA, USA., Lee GG; Pliant Therapeutics, South San Francisco, CA, USA., Rexhepaj M; Pliant Therapeutics, South San Francisco, CA, USA., Ho SS; Pliant Therapeutics, South San Francisco, CA, USA., Rao V; Pliant Therapeutics, South San Francisco, CA, USA., Marlow MM; Pliant Therapeutics, South San Francisco, CA, USA., Kotak P; Pliant Therapeutics, South San Francisco, CA, USA., Budi EH; Pliant Therapeutics, South San Francisco, CA, USA., Hooi L; Pliant Therapeutics, South San Francisco, CA, USA., Wu J; Pliant Therapeutics, South San Francisco, CA, USA., Fridlib M; Pliant Therapeutics, South San Francisco, CA, USA., Martin SP; Pliant Therapeutics, South San Francisco, CA, USA., Huang S; Pliant Therapeutics, South San Francisco, CA, USA., Chen M; Pliant Therapeutics, South San Francisco, CA, USA., Muñoz M; Pliant Therapeutics, South San Francisco, CA, USA., Hom TF; Pliant Therapeutics, South San Francisco, CA, USA., Wolters PJ; Department of Medicine, University of California, San Francisco, CA, USA., Desai TJ; Department of Medicine, Stanford University, Stanford, CA, USA., Rock F; Pliant Therapeutics, South San Francisco, CA, USA., Leftheris K; Pliant Therapeutics, South San Francisco, CA, USA., Morgans DJ; Pliant Therapeutics, South San Francisco, CA, USA.; Maze Therapeutics, South San Francisco, CA, USA., Lepist EI; Pliant Therapeutics, South San Francisco, CA, USA., Andre P; Pliant Therapeutics, South San Francisco, CA, USA.; Acceleron Pharma, Cambridge, MA, USA., Lefebvre EA; Pliant Therapeutics, South San Francisco, CA, USA., Turner SM; Pliant Therapeutics, South San Francisco, CA, USA. sturner@pliantrx.com.

Publikováno v: Respiratory research [Respir Res] 2021 Oct 19; Vol. 22 (1), pp. 265. Date of Electronic Publication: 2021 Oct 19.

Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β Inhibitor.

Autor: Chandrasekhar J; Gilead Sciences, Inc. , 199 East Blaine Street , Seattle , Washington 98102 , United States., Dick R; Gilead Sciences, Inc. , 333 Lakeside Drive , Foster City , California 94404 , United States., Van Veldhuizen J; Gilead Sciences, Inc. , 199 East Blaine Street , Seattle , Washington 98102 , United States., Koditek D; Gilead Sciences, Inc. , 333 Lakeside Drive , Foster City , California 94404 , United States., Lepist EI, McGrath ME; Gilead Sciences, Inc. , 333 Lakeside Drive , Foster City , California 94404 , United States., Patel L; Gilead Sciences, Inc. , 199 East Blaine Street , Seattle , Washington 98102 , United States., Phillips G; Gilead Sciences, Inc. , 199 East Blaine Street , Seattle , Washington 98102 , United States., Sedillo K; Gilead Sciences, Inc. , 199 East Blaine Street , Seattle , Washington 98102 , United States., Somoza JR; Gilead Sciences, Inc. , 333 Lakeside Drive , Foster City , California 94404 , United States., Therrien J; Gilead Sciences, Inc. , 199 East Blaine Street , Seattle , Washington 98102 , United States., Till NA, Treiberg J; Gilead Sciences, Inc. , 199 East Blaine Street , Seattle , Washington 98102 , United States., Villaseñor AG; Gilead Sciences, Inc. , 333 Lakeside Drive , Foster City , California 94404 , United States., Zherebina Y; Gilead Sciences, Inc. , 333 Lakeside Drive , Foster City , California 94404 , United States., Perreault S; Gilead Sciences, Inc. , 199 East Blaine Street , Seattle , Washington 98102 , United States.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2018 Aug 09; Vol. 61 (15), pp. 6858-6868. Date of Electronic Publication: 2018 Jul 30.